Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (30)

Antic J. (1,2), Chenel M. (2), Laffont C. M. (1), Concordet D. (1).

Nonparametric Methods: When to use them? Which method to choose?

Diane D. Wang, Shuzhong Zhang

Standardized Visual Predictive Check – How and When to used it in Model Evaluation

E. Jager(1), V. H.J. van der Velden(2), J. G. te Marvelde(2), R. B. Walter(3,4), Z. Agur(1,6), V. Vainstein(1,5).

Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based pharmacokinetic model for treatment strategy improvement and prediction of individual responses.

Andreas Kuttler, Thomas Dimke, Steven Kern, Gabriel Helmlinger, Luca A. Finelli

A 3D Computational Model Of Cerebrospinal Fluid Dynamics For Predictive Biosimulation

WS Denney (1), Y Hang (2), MF Dockendorf (1), C-C Li (1), SR Eid (3), R Valesky (1), T Laethem (5), P Van Hoydonck (5), I DeLepeleire (5), JNJM de Hoon (6), M Crutchlow (4), R Blanchard (4)

Modeling and Simulation for Determination of the Therapeutic Window of MK-2295: a TRPV1 Antagonist

W.H.O. Clausen (1), B.B.Rønn (1) I.M.Skovgaard (2)

Maximum likelihood estimation in nonlinear mixed effect models: Adaptive Gaussian Quadrature by sparse grid sampling

Venkata Pavan Kumar Vajjah, Stephen B Duffull

Novel graphical diagnostics for assessing fit of logistic regression models

Elena Soto(1), Alexander Staab(2), Gerd Munzert(2), Holger Fritsch(2), and Iñaki F. Trocóniz(1)

Prediction of haematological effects of a new combination of anticancer drugs, BI 2536 (a PLK1 inhibitor) and pemetrexed, using a semi-mechanistic population model for neutropenia

David Ternant (1,2), Emilie Hénin (1), Guillaume Cartron (3), Michel Tod (1), Gilles Paintaud (1), Pascal Girard (1)

Model-based optimization of rituximab dosing regimen in follicular non-Hogdkin lymphoma

Catherijne Knibbe

Are Children Small Adults: What can modeling offer to (clinical) practice?

Robert J. Bauer and Thomas M. Ludden

Improvements and New Estimation Methods in NONMEM 7 for PK/PD Population Analysis

B. Ribba, E. Watkin, M. Tod, P. Girard, B. You, B. Tranchand, E. Grenier, G. Freyer

Estimating the kinetic parameters of vascular tumor growth models to optimize anti-angiogenesis drugs delivery

Joakim Nyberg, Mats O. Karlsson, Andrew C. Hooker

Population optimal experimental design for discrete type data

Brian Anderson

Are Children Small Adults?

N. Gobeau, B. Boulanger, L.Sargentini-Maier

Comparison of different tools for the optimization of a pediatric clinical trial

Michael Looby, Guenther Kaiser, Beatrice Abrams and Bill Sallas

Elucidation of the optimal dosing scheme of an antiviral drug in children

Ron J Keizer (1), Anubha Gupta (2), Mendel Jansen (2), Jantien Wanders (2), Jos H Beijnen (1,4), Jan HM Schellens (3), Mats O Karlsson (5), Alwin DR Huitema (1)

Modeling of hypertension in response to anti-angiogenic therapy

Robert M. Kalicki, Rocío Lledó-García, Mats O. Karlsson

Modeling of Red Blood Cell (RBC) Lifespan (LS) in a Hematologically Normal Population

F.Stringer (1), B.Ploeger (2,3), J. de Jongh (2,3), G.Scott (1), R Urquart (5), A.Karim (4) and M. Danhof (2,3)

Genotyped versus phenotyped dosing to account for UGT polymorphism of the novel PPAR agonist sipoglitazar

Bertrand J (1), Comets E (1), Laffont CM (2), Chenel M (3), Mentré F (1)

Model-based tests to detect gene effect in pharmacokinetic studies

Matthew M. Hutmacher(1) and Jonathan L. French(2)

Estimating Transformations for Population Models of Continuous, Closed Interval Data

Laffont C. M., Concordet D.

A new exact test to globally assess a population PK and/or PD model

Marc Lavielle (1) and Radojka M. Savic (2)